Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Implementing anti-retroviral therapy in resource-constrained settings: a randomized controlled trial to assess the effect of integrated tuberculosis and HIV care on the incidence of AIDS-defining conditions or mortality in subjects co-infected with tuberculosis and HIV

Next Previous
X
Search
Trial Profile

Implementing anti-retroviral therapy in resource-constrained settings: a randomized controlled trial to assess the effect of integrated tuberculosis and HIV care on the incidence of AIDS-defining conditions or mortality in subjects co-infected with tuberculosis and HIV

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antituberculars; Didanosine; Efavirenz; Isoniazid/rifampicin; Lamivudine; Rifampicin/isoniazid/pyrazinamide/ethambutol
  • Indications HIV infections; Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Acronyms START

    • Most Recent Events

    • 23 Nov 2011 Results of the pharmacokinetic sub-study published in the European Journal of Clinical Pharmacology.
    • 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Mar 2010 Biomarkers information updated

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top